These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 35830552

  • 1. Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
    McElree IM, Packiam VT, Steinberg RL, Mott SL, Gellhaus PT, Nepple KG, O'Donnell MA.
    J Urol; 2022 Nov; 208(5):969-977. PubMed ID: 35830552
    [Abstract] [Full Text] [Related]

  • 2. Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
    McElree IM, Steinberg RL, Martin AC, Richards J, Mott SL, Gellhaus PT, Nepple KG, O'Donnell MA, Packiam VT.
    J Urol; 2022 Sep; 208(3):589-599. PubMed ID: 35892270
    [Abstract] [Full Text] [Related]

  • 3. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer.
    Chevuru PT, McElree IM, Mott SL, Steinberg RL, O'Donnell MA, Packiam VT.
    Urol Oncol; 2023 Mar; 41(3):148.e1-148.e7. PubMed ID: 36456454
    [Abstract] [Full Text] [Related]

  • 4. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
    Dinney CP, Greenberg RE, Steinberg GD.
    Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
    Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M.
    J Urol; 2000 Mar; 163(3):761-7. PubMed ID: 10687972
    [Abstract] [Full Text] [Related]

  • 6. Sequential intravesical gemcitabine and docetaxel for treatment-naïve and previously treated intermediate-risk nonmuscle invasive bladder cancer.
    McElree IM, Orzel J, Stubbee R, Steinberg RL, Mott SL, O'Donnell MA, Packiam VT.
    Urol Oncol; 2023 Dec; 41(12):485.e1-485.e7. PubMed ID: 37442741
    [Abstract] [Full Text] [Related]

  • 7. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
    Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA.
    J Urol; 2020 May; 203(5):902-909. PubMed ID: 31821066
    [Abstract] [Full Text] [Related]

  • 8. Early experience with sequential intravesical gemcitabine and docetaxel for micropapillary variant non-muscle invasive bladder cancer.
    Abou Chakra M, McElree IM, Packiam VT, Mott SL, O'Donnell MA.
    Urol Oncol; 2024 Sep; 42(9):289.e13-289.e21. PubMed ID: 38796357
    [Abstract] [Full Text] [Related]

  • 9. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
    Barlow LJ, McKiernan JM, Benson MC.
    J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
    [Abstract] [Full Text] [Related]

  • 10. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
    Yim K, Melnick K, Mott SL, Carvalho FLF, Zafar A, Clinton TN, Mossanen M, Steele GS, Hirsch M, Rizzo N, Wu CL, Mouw KW, Wszolek M, Salari K, Feldman A, Kibel AS, O'Donnell MA, Preston MA.
    Urol Oncol; 2023 Nov; 41(11):458.e1-458.e7. PubMed ID: 37690933
    [Abstract] [Full Text] [Related]

  • 11. Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
    Steinberg RL, Packiam VT, Thomas LJ, Brooks N, Vitale A, Mott SL, Crump T, Wang J, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA.
    Urol Oncol; 2022 Jan; 40(1):9.e1-9.e7. PubMed ID: 34092482
    [Abstract] [Full Text] [Related]

  • 12. A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
    Patel SH, Gabrielson AT, Chan S, Schwartz D, Collins C, Singla N, Trock B, Bivalacqua TJ, Hahn N, Kates MR.
    J Urol; 2024 Jul; 212(1):95-103. PubMed ID: 38653234
    [Abstract] [Full Text] [Related]

  • 13. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
    Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM.
    Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
    [Abstract] [Full Text] [Related]

  • 14. Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
    Sternberg IA, Dalbagni G, Chen LY, Donat SM, Bochner BH, Herr HW.
    J Urol; 2013 Nov; 190(5):1686-91. PubMed ID: 23665400
    [Abstract] [Full Text] [Related]

  • 15. Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC).
    Farah NB, Ghanem R, Amr M.
    BMC Urol; 2014 Jan 27; 14():11. PubMed ID: 24468269
    [Abstract] [Full Text] [Related]

  • 16. Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.
    Robins DJ, Sui W, Matulay JT, Ghandour R, Anderson CB, DeCastro GJ, McKiernan JM.
    Urology; 2017 May 27; 103():149-153. PubMed ID: 28163086
    [Abstract] [Full Text] [Related]

  • 17. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
    McElree IM, Steinberg RL, Mott SL, O'Donnell MA, Packiam VT.
    JAMA Netw Open; 2023 Feb 01; 6(2):e230849. PubMed ID: 36853609
    [Abstract] [Full Text] [Related]

  • 18. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Chou R, Selph S, Buckley DI, Fu R, Griffin JC, Grusing S, Gore JL.
    J Urol; 2017 May 01; 197(5):1189-1199. PubMed ID: 28027868
    [Abstract] [Full Text] [Related]

  • 19. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
    Barlow L, McKiernan J, Sawczuk I, Benson M.
    BJU Int; 2009 Oct 01; 104(8):1098-102. PubMed ID: 19389012
    [Abstract] [Full Text] [Related]

  • 20. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
    DeCastro GJ, Sui W, Pak JS, Lee SM, Holder D, Kates MM, Virk RK, Drake CG, Anderson CB, James B, Abate-Shen CT, McKiernan JM.
    J Urol; 2020 Aug 01; 204(2):247-253. PubMed ID: 32118506
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.